Sodium-glucose cotransporter 2 inhibitors (SGLT2is) have shown promise in CKD treatment, irrespective of type 2 diabetes (T2D) status, offering both renal and cardiovascular benefits. This evidence concerns the gene SLC5A2 and chronic kidney disease.